|
Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early Breast Cancer, After Breast-conserving Surgery
RECRUITINGN/ASponsored by Instituto Brasileiro de Controle do Cancer
Actively Recruiting
PhaseN/A
SponsorInstituto Brasileiro de Controle do Cancer
Started2021-03-04
Est. completion2025-12-07
Eligibility
Age50 Years – 90 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT04669873
Summary
Radiotherapy has been confirmed as an important treatment breast-conserving surgery reducing the risk of any recurrence of breast cancer and breast cancer-related mortality in patients with early breast cancer. There are no comparative data on the ideal radiotherapy treatment regimen for patients with early stage breast cancer who underwent conservative surgery in the Brazilian population.
Eligibility
Age: 50 Years – 90 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria: * Information to the patient and signed informed consent; * Women aged ≥50 years * Breast conserving surgery * Pathologic tumor size \< 3 cm (maximum microscopic diameter of the invasive component) * Invasive adenocarcinoma (except classic invasive lobular carcinoma) * Unifocal disease * Histopathologic grades I or II * Eastern Cooperative Oncology Group (ECOG) 0-1 * Lymphovascular invasion absent * Negative axillary lymph nodes * Minimum microscopic margins of non-cancerous tissue of 2mm (excluding deep margin when in deep fascia) * No prior breast or mediastinal radiotherapy * No hematogenous metastases Exclusion Criteria: * Previous malignancy (except non-melanomatous skin cancer) * Mastectomy * Classical-Type Invasive Lobular Carcinoma * Neoadjuvant chemotherapy * Human Epidermal growth factor Receptor-type 2 positive (HER2+) * Triple-negative breast cancers * Intravascular lymphoma present * Contraindications to radiotherapy. * No geographical, social or psychologic reasons that would prevent study follow
Conditions3
Breast CancerCancerMalignant Neoplasm of Breast
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorInstituto Brasileiro de Controle do Cancer
Started2021-03-04
Est. completion2025-12-07
Eligibility
Age50 Years – 90 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT04669873